Epilepsy affects over 50 million people worldwide — making it one of the most common neurological conditions globally. In India, approximately 12 million people live with epilepsy. While many people associate epilepsy with brain injury or infection, genetics plays a far more significant role than most people realize. Understanding the genetic basis of epilepsy is transforming diagnosis, treatment, and family planning for affected individuals and families.
Is Epilepsy Genetic?
Yes — genetics contributes to epilepsy in a significant proportion of cases. Approximately 30–40% of epilepsy has a clear genetic basis, and genetic factors contribute to susceptibility in many more cases. The genetic architecture of epilepsy is complex: some forms are caused by single-gene mutations (monogenic epilepsies), while others result from the combined effect of many common genetic variants (polygenic epilepsies).
Types of Genetic Epilepsy
Monogenic Epilepsies
Caused by mutations in a single gene. These are often severe, early-onset epilepsies that are resistant to standard antiepileptic drugs. Examples include:
- Dravet syndrome: Caused by mutations in SCN1A (sodium channel gene). Characterized by prolonged febrile seizures in infancy, progressing to multiple seizure types. Responds poorly to sodium channel blockers.
- KCNQ2-related epilepsy: Caused by mutations in KCNQ2 (potassium channel gene). Often presents as neonatal seizures.
- CDKL5 deficiency disorder: Caused by mutations in CDKL5. Characterized by early-onset seizures and severe intellectual disability.
- Tuberous Sclerosis Complex (TSC): Caused by mutations in TSC1 or TSC2. Associated with benign tumors in multiple organs and epilepsy.
Genetic Generalized Epilepsies (GGE)
A group of epilepsies with strong genetic contributions but complex inheritance. Includes juvenile myoclonic epilepsy (JME), childhood absence epilepsy, and juvenile absence epilepsy. These typically respond well to appropriate antiepileptic medications.
Why Genetic Diagnosis Matters in Epilepsy
Identifying the genetic cause of epilepsy has profound clinical implications. It guides treatment selection — some genetic epilepsies respond to specific drugs while others are worsened by them (e.g., sodium channel blockers worsen Dravet syndrome). It enables accurate prognosis and family counselling. It identifies associated features that require monitoring (e.g., cardiac arrhythmias in SCN5A-related epilepsy). And it opens access to targeted therapies and clinical trials.
Pharmacogenomics in Epilepsy Treatment
Beyond identifying the cause of epilepsy, genetic testing can optimize treatment. Variants in genes like CYP2C9, CYP2C19, and UGT1A4 affect how antiepileptic drugs are metabolized — influencing both efficacy and side effect risk. Pharmacogenomic testing can help identify the right drug at the right dose from the start, reducing the trial-and-error that characterizes epilepsy management.
FAQs
If I have epilepsy, will my children have it?
The risk depends on the type of epilepsy and its genetic basis. For monogenic epilepsies, inheritance follows Mendelian patterns. For genetic generalized epilepsies, the risk to first-degree relatives is elevated but not certain. A genetic counsellor can provide personalized risk estimates based on your specific diagnosis.
What genetic tests are available for epilepsy?
Options include targeted gene panels (testing specific epilepsy-associated genes), whole exome sequencing (WES), and chromosomal microarray. The appropriate test depends on the clinical presentation and is best determined in consultation with a neurologist and genetic counsellor.
Get Genetic Answers for Neurological Conditions
MapmyGenome's genetic testing panels — including Whole Exome Sequencing and MedicaMap — help identify the genetic basis of epilepsy and optimize treatment through pharmacogenomic insights. Backed by NABL-certified labs and expert genetic counsellors.
